Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylphenidate extended-release oral suspension - Tris Pharma

Next Previous
Drug Profile

Methylphenidate extended-release oral suspension - Tris Pharma

Alternative Names: NWP 06; Quillivant ER; Quillivant XR

Latest Information Update: 03 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NextWave Pharmaceuticals
  • Developer Tris Pharma
  • Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 03 Dec 2024 Methylphenidate extended-release oral suspension - Tris Pharma is available for licensing as of 03 Dec 2024. http://www.trispharma.com
  • 01 Oct 2024 Registered for Attention-deficit hyperactivity disorder (In adolescents, In adults, In children, In the elderly) in Saudi Arabia (PO)
  • 01 Oct 2024 Registered for Attention-deficit hyperactivity disorder (In adults, In children, In adolescents, In the elderly) in Saudi Arabia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top